National Research Foundation Singapore
-
DATABASE (438)
-
ARTICLES (524)
Co-founder and CTO of Allozymes
Akbar Vahidi is an Iranian researcher turned entrepreneur based in Singapore. After graduating in 2010 with a bachelor’s in chemical engineering from Sharif University of Technology, he pursued a PhD in chemical and biomolecular engineering at the National University of Singapore (NUS). Vahidi earned his PhD in 2015 and briefly worked as a research fellow at Nanyang Technological University before returning to NUS to pursue research.At NUS, he was a part of a research group that developed a new enzyme screening method based on microfluidics technology. With fellow NUS PhD graduate Peyman Salehian, Vahidi secured an exclusive license to use the technology and established Allozymes, a startup that offers enzyme engineering services. Vahidi became the CTO of Allozymes.
Akbar Vahidi is an Iranian researcher turned entrepreneur based in Singapore. After graduating in 2010 with a bachelor’s in chemical engineering from Sharif University of Technology, he pursued a PhD in chemical and biomolecular engineering at the National University of Singapore (NUS). Vahidi earned his PhD in 2015 and briefly worked as a research fellow at Nanyang Technological University before returning to NUS to pursue research.At NUS, he was a part of a research group that developed a new enzyme screening method based on microfluidics technology. With fellow NUS PhD graduate Peyman Salehian, Vahidi secured an exclusive license to use the technology and established Allozymes, a startup that offers enzyme engineering services. Vahidi became the CTO of Allozymes.
CEO and Co-founder of Cambricon Technologies
Founder and CEO of Cambricon Technologies. Chen, who has more than 10 years of experience in the field of artificial intelligence, is a professor at the Chinese Academy of Sciences. He graduated from the Special Class for the Gifted Young of the University of Science and Technology of China, a program that selects and nurtures the most intelligent Chinese students. Chen has received financial support from the National Science Fund for Distinguished Young Scholars, which was launched by the National Natural Science Foundation of China.
Founder and CEO of Cambricon Technologies. Chen, who has more than 10 years of experience in the field of artificial intelligence, is a professor at the Chinese Academy of Sciences. He graduated from the Special Class for the Gifted Young of the University of Science and Technology of China, a program that selects and nurtures the most intelligent Chinese students. Chen has received financial support from the National Science Fund for Distinguished Young Scholars, which was launched by the National Natural Science Foundation of China.
CTO and Co-founder of Nusantics
Revata Utama has worked as an engineer and scientist in various biomedical R&D projects. After graduating from the National University of Singapore in 2012 with a bachelor's in Life and Biomedical Sciences, Utama joined Delta Electronics in 2013. He worked as a biomedical engineer from 2013 to 2017, as part of the R&D teams for joint projects with Singapore's Institute of Bioengineering and Nanotechnology (IBN) at Biopolis.In June 2017, he joined JN Medsys in Singapore to conduct research on polymerase chain reaction (PCR) chip projects. He left Medsys in January 2020 to return to Indonesia and run Nusantics full-time as CTO to lead the company's research into genomics-based services.
Revata Utama has worked as an engineer and scientist in various biomedical R&D projects. After graduating from the National University of Singapore in 2012 with a bachelor's in Life and Biomedical Sciences, Utama joined Delta Electronics in 2013. He worked as a biomedical engineer from 2013 to 2017, as part of the R&D teams for joint projects with Singapore's Institute of Bioengineering and Nanotechnology (IBN) at Biopolis.In June 2017, he joined JN Medsys in Singapore to conduct research on polymerase chain reaction (PCR) chip projects. He left Medsys in January 2020 to return to Indonesia and run Nusantics full-time as CTO to lead the company's research into genomics-based services.
Chairman of the Board, co-founder, co-inventor of NovoNutrients
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
LionRock Capital is a family investment office based in Singapore. LionRock Capital adopt a fundamental, bottom-up research process to invest in long duration investment themes with a focus on growing markets in Asia.
LionRock Capital is a family investment office based in Singapore. LionRock Capital adopt a fundamental, bottom-up research process to invest in long duration investment themes with a focus on growing markets in Asia.
Co-founder and CEO of Allozymes
Peyman Salehian is an Iranian-born entrepreneur trained in chemical and biomolecular engineering. He founded his first company in 2010 after developing a custom material, and sold his stake in the company in 2013 before pursuing a PhD in Chemical and Biomolecular engineering at the National University of Singapore (NUS).Salehian graduated from the PhD program in 2017 and worked as a research fellow before embarking on one-year stints at two Singapore companies. In late 2019, he and fellow NUS researcher Akbar Vahidi established Allozymes, a startup offering enzyme engineering services using NUS-developed technology under license, with Salehian as CEO and Vahidi as CTO.
Peyman Salehian is an Iranian-born entrepreneur trained in chemical and biomolecular engineering. He founded his first company in 2010 after developing a custom material, and sold his stake in the company in 2013 before pursuing a PhD in Chemical and Biomolecular engineering at the National University of Singapore (NUS).Salehian graduated from the PhD program in 2017 and worked as a research fellow before embarking on one-year stints at two Singapore companies. In late 2019, he and fellow NUS researcher Akbar Vahidi established Allozymes, a startup offering enzyme engineering services using NUS-developed technology under license, with Salehian as CEO and Vahidi as CTO.
Founder of Inibudi
Najelaa Shihab is an education philanthropist. She is the elder sister of Najwa Shihab, a well-known Indonesian presenter. After graduating in 1997, Najelaa established an international curriculum school foundation in 1999. She completed a master’s in 2002, also from her alma mater Faculty of Psychology, University of Indonesia.In 2016, she created Sinedu, an online kid-safe educational movies platform and Youthmanual, a career portal for youths. She also founded an Education and Policy Research Institution in 2015 and a teachers’ professional development and school foundation in 2014. She also supports Indonesia’s breastfeeding mothers’ association AIMI.
Najelaa Shihab is an education philanthropist. She is the elder sister of Najwa Shihab, a well-known Indonesian presenter. After graduating in 1997, Najelaa established an international curriculum school foundation in 1999. She completed a master’s in 2002, also from her alma mater Faculty of Psychology, University of Indonesia.In 2016, she created Sinedu, an online kid-safe educational movies platform and Youthmanual, a career portal for youths. She also founded an Education and Policy Research Institution in 2015 and a teachers’ professional development and school foundation in 2014. She also supports Indonesia’s breastfeeding mothers’ association AIMI.
NewMargin Ventures is a venture capital management firm in China focused on the IT, sustainable growth technology, biomedicine and high margin manufacturing sectors. Its Chinese investors include China Foundation of Science & Technology for Development (a joint venture between the National Development and Reform Commission, the Ministry of Commerce and Chinese Academy of Sciences) and Shanghai Alliance Investment Co. (an investment firm founded by Jiang Mianheng, son of the former Chinese President Jiang Zemin); and its foreign investors include GIC, Kerry Group, K.Wah Group, SUNeVision, JAFCO, Motorola and Alcatel. NewMargin Ventures has invested more than US$1.7 billion in 160 companies, including 40 IPOs.
NewMargin Ventures is a venture capital management firm in China focused on the IT, sustainable growth technology, biomedicine and high margin manufacturing sectors. Its Chinese investors include China Foundation of Science & Technology for Development (a joint venture between the National Development and Reform Commission, the Ministry of Commerce and Chinese Academy of Sciences) and Shanghai Alliance Investment Co. (an investment firm founded by Jiang Mianheng, son of the former Chinese President Jiang Zemin); and its foreign investors include GIC, Kerry Group, K.Wah Group, SUNeVision, JAFCO, Motorola and Alcatel. NewMargin Ventures has invested more than US$1.7 billion in 160 companies, including 40 IPOs.
Rick Klausner is an award-winning scientist, former executive director of the Bill & Melinda Gates Foundation and an entrepreneur. Cell and molecular biologist Klausner was also director of the US National Cancer Institute from 1999-2001 and currently serves as CEO at biotech Lyell Immunopharma working with cell-based technology. He has also co-founded three US healthcare startups to date, Juno Therapeutics in 2013, MindStrong Health in 2014 and GRAIL in 2015. In 2021, he participated as an investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Rick Klausner is an award-winning scientist, former executive director of the Bill & Melinda Gates Foundation and an entrepreneur. Cell and molecular biologist Klausner was also director of the US National Cancer Institute from 1999-2001 and currently serves as CEO at biotech Lyell Immunopharma working with cell-based technology. He has also co-founded three US healthcare startups to date, Juno Therapeutics in 2013, MindStrong Health in 2014 and GRAIL in 2015. In 2021, he participated as an investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
CEO and founder of Neliti
Biologist-turned-entrepreneur Anton Lucanus' entrepreneurial journey began in Indonesia, where he established research database service Neliti in 2016. He is also the founder and CEO of Reputio, a US-based digital PR firm. Lucanus graduated with a bachelor's in Anatomy and Human Biology from the University of Western Australia. He had also taken a minor in Indonesian as part of a student exchange program at Universitas Gadjah Mada, Indonesia. In 2015, Lucanus had a brief stint as a researcher at the Eijkman Institute before earning his master's in Oncology and Cancer Biology at the National University of Singapore.
Biologist-turned-entrepreneur Anton Lucanus' entrepreneurial journey began in Indonesia, where he established research database service Neliti in 2016. He is also the founder and CEO of Reputio, a US-based digital PR firm. Lucanus graduated with a bachelor's in Anatomy and Human Biology from the University of Western Australia. He had also taken a minor in Indonesian as part of a student exchange program at Universitas Gadjah Mada, Indonesia. In 2015, Lucanus had a brief stint as a researcher at the Eijkman Institute before earning his master's in Oncology and Cancer Biology at the National University of Singapore.
Founder and CEO of Veniam
Cornell and Stanford-educated Fulbright scholar João Barros is a professor of Electrical and Computer Engineering at the University of Porto and teaches in the MBA program at the Porto Business School. He has also held visiting appointments at MIT and Carnegie Mellon. He has co-founded two startups, Streambolico and Veniam, of which he is also CEO. Between 2009 and 2012, Barros served as National Director of the Carnegie Mellon Portugal Program, a five-year international partnership funded by the Portuguese Foundation of Science and Technology. He holds a Ph.D. in Electrical Engineering and Information Technology from Munich's Technical University.
Cornell and Stanford-educated Fulbright scholar João Barros is a professor of Electrical and Computer Engineering at the University of Porto and teaches in the MBA program at the Porto Business School. He has also held visiting appointments at MIT and Carnegie Mellon. He has co-founded two startups, Streambolico and Veniam, of which he is also CEO. Between 2009 and 2012, Barros served as National Director of the Carnegie Mellon Portugal Program, a five-year international partnership funded by the Portuguese Foundation of Science and Technology. He holds a Ph.D. in Electrical Engineering and Information Technology from Munich's Technical University.
Co-founder of Therapixal
Olivier Clatz is the French co-founder of AI medical diagnosis company Therapixel, creator of MammoScreen breast cancer screening and diagnosis tool. Prior to co-founding Therapixel, Clatz worked for six years as a research scientist at INRIA (National Institute for Research in Digital Science and Technology) based at the Sophia Antipolis technology park near Antibes, in the south of France. His later work with INRIA focused on exploiting machine learning algorithms for medical imaging processing. Prior to this, he was a research associate at Harvard Medical School, in the US. In 2006, he completed his PhD at INRIA on the concept of personalized medicine. Clatz also holds a PhD in philosophy from the Ecole des Mines de Paris, and a master's degree in applied mathematics from the Ecole Normale Supérieure Paris-Saclay. Currently, he works at the French Government’s Commissariat Générale pour l’Investissement managing the national program AI For Diagnostics. He left Therapixel in 2019.
Olivier Clatz is the French co-founder of AI medical diagnosis company Therapixel, creator of MammoScreen breast cancer screening and diagnosis tool. Prior to co-founding Therapixel, Clatz worked for six years as a research scientist at INRIA (National Institute for Research in Digital Science and Technology) based at the Sophia Antipolis technology park near Antibes, in the south of France. His later work with INRIA focused on exploiting machine learning algorithms for medical imaging processing. Prior to this, he was a research associate at Harvard Medical School, in the US. In 2006, he completed his PhD at INRIA on the concept of personalized medicine. Clatz also holds a PhD in philosophy from the Ecole des Mines de Paris, and a master's degree in applied mathematics from the Ecole Normale Supérieure Paris-Saclay. Currently, he works at the French Government’s Commissariat Générale pour l’Investissement managing the national program AI For Diagnostics. He left Therapixel in 2019.
Co-Founder and CTO of Bridestory
Ex-SingTel software analyst Doni Hanafi holds a Bachelor of Engineering degree in Electrical and Electronic Engineering from Nanyang Technological University and a Master of Computing degree in Computer Science from the National University of Singapore.
Ex-SingTel software analyst Doni Hanafi holds a Bachelor of Engineering degree in Electrical and Electronic Engineering from Nanyang Technological University and a Master of Computing degree in Computer Science from the National University of Singapore.
Co-founder and CTO of Ahlijasa
Made Dimas Astra Wijaya was a former assistant vice president at the Bank of America Merrill Lynch. He left the bank after four years in 2015 and joined Jay Jayawijayaningtyas to set up Ahlijasa. He has an Information Systems degree from the Singapore Management University and a master’s in Computing from the National University of Singapore.
Made Dimas Astra Wijaya was a former assistant vice president at the Bank of America Merrill Lynch. He left the bank after four years in 2015 and joined Jay Jayawijayaningtyas to set up Ahlijasa. He has an Information Systems degree from the Singapore Management University and a master’s in Computing from the National University of Singapore.
CEO and co-founder of SmartAHC
Lan Song completed a PhD in integrated circuit design at Nanyang Technological University in Singapore. He worked as a research engineer at Rolls-Royce@NTU Corporate Lab, a joint corporate research venture in Singapore.His family used to be in the husbandry business that partly inspired Lan to co-found SmartAHC with classmates in 2014. He currently serves as CEO at SmartAHC.
Lan Song completed a PhD in integrated circuit design at Nanyang Technological University in Singapore. He worked as a research engineer at Rolls-Royce@NTU Corporate Lab, a joint corporate research venture in Singapore.His family used to be in the husbandry business that partly inspired Lan to co-found SmartAHC with classmates in 2014. He currently serves as CEO at SmartAHC.
Meatable: Cell-based meat startup secures $47m Series A for scalable technology
The Dutch startup offers a pioneering technology for quickly scaling cell-based meat production while eliminating the need for animal-derived growth media
Allozymes wants to supercharge manufacturing with engineered enzymes
The Future Food Asia 2021 award winner speeds up enzyme engineering from years to months, is already attracting clients and has just raised $5m seed funding
Circular economy: Discarded goods get a new lease of life in Spain
From e-chargers inside phone booths, recycling chatbots to refurbished stadium seats from Atlético Madrid, the offbeat magic of the circular economy is fast becoming a lucrative business in Spain
SmartAHC: Wearables for pigs and smart farm management to boost productivity
SmartAHC has also expanded beyond pig farms to related sectors in the supply chain, including insurance, banking and local government
ARTICARES: Personalized, more affordable arm rehab therapy at home
Using adaptive AI, its H-Man robot works like an occupational therapist, assessing patient’s performance and adjusting the complexity of training tasks in real time
Pula: Pioneering insurtech helps to improve Africa's food security
With Kenyan insurtech Pula’s micro-insurance products, millions of farmers no longer have to bear the full risk of losses from natural disasters and crop failures
Sophie's Bionutrients: Alternative protein from microalgae
Inspired by fish in the ocean, the startup developed microalgae-based flour that can take on unlimited forms, textures or colors to make almost any alt protein product
MENA and Du’Anyam: How two Indonesian social enterprises are tackling Covid-19 challenges
The call to help women in rural communities has become more urgent as social enterprises struggle to survive the current crisis
US non-profit investor New Energy Nexus seeks to kickstart Indonesia’s clean energy sectors
With a “patient capital” approach to investments and a variety of programs, New Energy Nexus hopes to show that startups can lead the way in renewables and smart energy
HighPitch 2020: Goers wins Indonesia's national startup competition
Event ticketing startup Goers gains new revenue streams with pivot to helping leisure spots go online; hotel SaaS Izy and on-demand medical testing service CekLab also in top three
Bringing Indonesia's research to the world: Interview with Anton Lucanus, Neliti CEO
The former biologist talks about online repositories and his vision for improving Indonesia's research culture
Indonesian state enterprises launch e-wallet LinkAja, competing with Go-Pay and OVO
Even with a wider range of services and extensive state backing, LinkAja faces a tough battle
MSMB: From university research to agritech ecosystem
The Indonesian startup is moving beyond sensors to build technologies for livestock tracking and fish farming
SWITCH Singapore 2021: Benefits and challenges of AI applications in healthcare
Medical experts and healthcare startups agree AI can contribute more to healthcare beyond improving diagnosis and personalized treatment, but hurdles still remain
Bukalapak CEO Achmad Zaky steps down, ex-banker Rachmat Kaimuddin to take over
Rumors of a leadership change first surfaced in August as the Indonesian unicorn and its co-founder got a bad press
Sorry, we couldn’t find any matches for “National Research Foundation Singapore”.
